GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aceragen Inc (NAS:ACGN) » Definitions » E10

Aceragen (Aceragen) E10 : $-52.51 (As of Mar. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Aceragen E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Aceragen's adjusted earnings per share data for the three months ended in Mar. 2023 was $-2.940. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-52.51 for the trailing ten years ended in Mar. 2023.

During the past 3 years, the average E10 Growth Rate was -8.50% per year. During the past 5 years, the average E10 Growth Rate was -18.30% per year. During the past 10 years, the average E10 Growth Rate was -16.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Aceragen was 79.20% per year. The lowest was -212.10% per year. And the median was -13.20% per year.

As of today (2024-05-20), Aceragen's current stock price is $0.38. Aceragen's E10 for the quarter that ended in Mar. 2023 was $-52.51. Aceragen's Shiller PE Ratio of today is .


Aceragen E10 Historical Data

The historical data trend for Aceragen's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aceragen E10 Chart

Aceragen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -69.75 -79.59 -74.60 -63.20 -53.95

Aceragen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -61.04 -60.45 -57.68 -53.95 -52.51

Competitive Comparison of Aceragen's E10

For the Biotechnology subindustry, Aceragen's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aceragen's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aceragen's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Aceragen's Shiller PE Ratio falls into.



Aceragen E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Aceragen's adjusted earnings per share data for the three months ended in Mar. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2023 (Change)*Current CPI (Mar. 2023)
=-2.94/127.3478*127.3478
=-2.940

Current CPI (Mar. 2023) = 127.3478.

Aceragen Quarterly Data

per share eps CPI Adj_EPS
201306 -20.400 98.518 -26.370
201309 -14.960 98.790 -19.285
201312 -10.880 98.326 -14.091
201403 -16.320 99.695 -20.847
201406 -13.600 100.560 -17.223
201409 -14.960 100.428 -18.970
201412 -19.040 99.070 -24.475
201503 -16.320 99.621 -20.862
201506 -14.960 100.684 -18.922
201509 -13.600 100.392 -17.252
201512 -13.600 99.792 -17.355
201603 -14.960 100.470 -18.962
201606 -14.960 101.688 -18.735
201609 -13.600 101.861 -17.003
201612 2.550 101.863 3.188
201703 -13.600 102.862 -16.837
201706 -19.550 103.349 -24.090
201709 -13.260 104.136 -16.216
201712 -10.540 104.011 -12.905
201803 -13.770 105.290 -16.655
201806 -10.030 106.317 -12.014
201809 -7.310 106.507 -8.740
201812 -7.650 105.998 -9.191
201903 -6.800 107.251 -8.074
201906 -6.630 108.070 -7.813
201909 -6.630 108.329 -7.794
201912 -29.920 108.420 -35.143
202003 3.740 108.902 4.374
202006 -12.240 108.767 -14.331
202009 -10.030 109.815 -11.631
202012 -35.870 109.897 -41.566
202103 -2.380 111.754 -2.712
202106 -2.550 114.631 -2.833
202109 -1.870 115.734 -2.058
202112 -1.360 117.630 -1.472
202203 -1.340 121.301 -1.407
202206 -1.700 125.017 -1.732
202209 -1.020 125.227 -1.037
202212 -3.097 125.222 -3.150
202303 -2.940 127.348 -2.940

Add all the adjusted EPS together and divide 10 will get our e10.


Aceragen  (NAS:ACGN) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Aceragen E10 Related Terms

Thank you for viewing the detailed overview of Aceragen's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Aceragen (Aceragen) Business Description

Traded in Other Exchanges
N/A
Address
505 Eagleview Boulevard, Suite 212, Exton, PA, USA, 19341
Aceragen Inc is a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases. The company portfolio includes late-stage programs based on well-established biological principles that are developing to be inventive therapeutics capable of addressing the unmet medical needs of individuals living with rare diseases.
Executives
Vincent Milano director, officer: President & CEO C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Maxine Gowen director
Pillar Invest Corp director, 10 percent owner C/O PILLAR INVEST OFFSHORE SAL, STARCO CENTER, BLOC B FL3, OMAR DAOUK ST, BEIRUT M8 2020-3313
Atul Chopra 10 percent owner C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
John Clayton Taylor director, officer: Chief Executive Officer C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
Carl N Kraus officer: Chief Medical Officer C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
Andrew R Jordan officer: Chief Strategy Officer C/O GUILFORD PHARMACEUTICALS INC, 6611 TIBUTARY ST., BALTIMORE MD 21224
Daniel Salain officer: Chief Operating Officer C/O GRAYBUG VISION, INC., 275 SHORELINE DRIVE, SUITE 450, REDWOOD CITY CA 94065
Ronald J Wooten director
Nq Pof V Gp, Ltd. director, other: See Remarks 4208 SIX FORKS ROAD, SUITE 920, RALEIGH NC 27609
Novaquest Co-investment Fund Xv, L.p. director, other: See Remarks 4208 SIX FORKS ROAD, SUITE 920, RALEIGH NC 27609
John J. Kirby officer: V.P. of Finance, PFO & PAO C/O IDERA PHARMACEUTICALS, INC., 505 EAGLEVIEW BLVD., SUITE 212, EXTON PA 19341
Michael R Dougherty director C/O ADOLOR CORP, 700 PENNSYLVANIA DR, EXTON PA 19341
Elizabeth Ann Tarka officer: Chief Medical Officer 111 WAVERLY CIRCLE, PHOENIXVILLE PA 19460
Bryant David Lim officer: SVP & General Counsel C/O IDERA PHARMACEUTICALS, INC., 505 EAGLEVIEW BLVD., SUITE 212, EXTON PA 19341

Aceragen (Aceragen) Headlines